Beryl Drugs Ltd

Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 8 July 2026. This change reflects a combination of improved technical indicators, attractive valuation metrics, positive quarterly financial results, and rising promoter confidence, despite some lingering concerns over long-term fundamentals.

Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a very attractive rating. This change reflects a significant improvement in price metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, positioning the stock as a more compelling option relative to its historical averages and peer group.

Beryl Drugs Ltd., an Indore-based pharmaceutical manufacturer specialising in intravenous fluids and injectable formulations, reported a remarkable turnaround in Q4 FY26 (January-March 2026), posting net profit of ₹0.56 crores compared to a loss of ₹0.17 crores in the previous quarter. The micro-cap company, with a market capitalisation of just ₹11.00 crores, demonstrated strong sequential momentum with revenue surging 35.71% quarter-on-quarter to ₹5.13 crores, whilst operating margins expanded dramatically to 26.12% from negative territory in Q3 FY26.

Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has demonstrated a notable financial turnaround in the quarter ended March 2026. The company’s financial trend shifted from flat to positive, with key profitability metrics reaching their highest levels in recent quarters, signalling a potential inflection point for investors amid a challenging market backdrop.

Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 6 May 2026. This revision reflects deteriorating technical indicators, flat financial performance, and weak long-term fundamentals despite some valuation appeal and rising promoter confidence.

Beryl Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 7 April 2026. This change reflects a nuanced shift in the company’s technical outlook despite ongoing challenges in its financial performance and valuation metrics.

Beryl Drugs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 6 March 2026. This shift reflects deteriorating technical indicators, flat financial performance, and weak long-term fundamentals, despite an attractive valuation. The company’s stock price has also suffered, declining 7.10% on the day of the downgrade, underscoring investor concerns.

Beryl Drugs Ltd’s share price declined to a fresh 52-week low of Rs.15.92 today, marking a significant milestone in the stock’s ongoing downward trajectory. This new low reflects persistent challenges faced by the company within the Pharmaceuticals & Biotechnology sector, as it continues to underperform both its sector peers and broader market indices.

Beryl Drugs Ltd’s shares declined sharply to a fresh 52-week low of Rs.16.2 today, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s stock has underperformed its sector and broader market indices, reflecting persistent pressures on its financial performance and valuation metrics.

Beryl Drugs Ltd. reported a troubling Q3 FY26 performance, posting a net loss of ₹0.17 crores against a profit of ₹0.05 crores in the same quarter last year, marking a complete reversal in profitability. The micro-cap pharmaceutical manufacturer saw revenues decline 28.81% year-on-year to ₹3.78 crores, whilst operating margins turned sharply negative at -5.29%, down from 11.11% in Q3 FY25. The stock, trading at ₹22.00 with a market capitalisation of ₹11.00 crores, has underperformed dramatically, falling 33.66% over the past year against the Sensex's 7.97% gain.

Beryl Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 December 2025, providing investors with an up-to-date view of the company's fundamentals, returns, and market performance.

Beryl Drugs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key analytical parameters. This adjustment comes amid a backdrop of mixed financial performance and market returns, offering investors a fresh perspective on the stock’s current standing.